A Phase 2 Multi-Centre, Randomised, Double-Blind, Placebo Controlled, Dose Ranging Study Of TBC3711 In Subjects With Resistant Hypertension.
Phase of Trial: Phase II
Latest Information Update: 04 Mar 2013
At a glance
- Drugs TBC 3711 (Primary)
- Indications Hypertension
- Focus Adverse reactions
- 08 Jun 2011 Actual initiation date changed from Mar 2007 to Jan 2006 as reported by ClinicalTrials.gov.
- 08 Jun 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 08 Jun 2011 Planned end date changed from 1 Mar 2008 to 1 Aug 2008 as reported by ClinicalTrials.gov.